|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Monocyte chemoattractant protein-1, transforming growth factor-β1, nerve growth factor, resistin and hyaluronic acid as serum markers:comparison between recurrent acute and chronic pancreatitis显示文摘BACKGROUND: Diagnostic parameters that can predict the presence of chronic pancreatitis(CP) in patients with recurrent pain due to pancreatitis would help to direct appropriate therapy. This study aimed to compare the serum levels of monocyte chemoattractant protein-1(MCP-1), transforming growth factor-β1(TGF-β1), nerve growth factor(NGF), resistin and hyaluronic acid(HA) in patients with recurrent acute pancreatitis(RAP) and CP to assess their ability to differentiate the two conditions.METHODS: Levels of serum markers assessed by enzymelinked immunosorbent assay(ELISA) were prospectively compared in consecutive patients with RAP, CP and in controls and stepwise discriminant analysis was performed to identify the markers differentiating RAP from CP.RESULTS: One hundred and thirteen consecutive patients(RAP=32, CP=81) and 78 healthy controls were prospectively enrolled. The mean(SD) age of the patients was 32.0(14.0)years; 89(78.8%) were male. All markers were significantly higher in CP patients than in the controls(P<0.001); MCP-1NGF and HA were significantly higher in RAP patients than in the controls(P<0.001). Stepwise discriminant analysis showed significant difference(P=0.002) between RAP and CP for resistin with an accuracy of 61.9%, discriminant scores of ≤-0.479 and ≥0.189 indicating RAP and CP, respectively. The other markers had no differential value between RAP and CP.CONCLUSION: Serum resistin is a promising marker to differentiate between RAP and CP and needs validation in future studies, especially in those with early CP. | M Ganesh Kamath C Ganesh Pai Asha Kamath Annamma Kurien | 2016 | Hepatobiliary & Pancreatic Diseases International2016，15，2： | 7 |
| 2 | Gut microbiome in primary sclerosing cholangitis:A review显示文摘Primary sclerosing cholangitis(PSC)is a chronic cholestatic liver disease characterized by biliary inflammation and stricturing.Exploration of the pathogenesis of PSC in light of its association with inflammatory bowel disease(IBD)and the“gut-liver”axis is an emerging area of interest.A growing number of studies have begun to elucidate the role of the gut microbiota,its metabolites and its influence on host immune responses in the development of PSC and PSCIBD.Studies of the fecal microbiota have highlighted enriched levels of certain species,including Veillonella,Streptococcus and Enterococcus,among others.A heightened immune response to enteric dysbiosis and bacterial translocation have also been implicated.For example,Klebsiella pneumoniae strains derived from gnotobiotic mice transplanted with PSC-IBD microbiota were found to induce pore formation in human intestinal epithelial cells and enhanced Th17 responses.Gut microbes have additionally been hypothesized to be implicated in PSC pathogenesis through their role in the synthesis of various metabolites,including bile acids(BAs),which function as signaling molecules with important gut and hepatic effects.An expanded knowledge of the gut microbiome as it relates to PSC offers critical insight into the development of microbe-altering therapeutic interventions,such as antibiotics,nutritional interventions and fecal microbial transplantation.Some of these have already shown some preliminary evidence of benefit.Despite exciting progress in the field,much work remains to be done;areas that are particularly lacking include functional characterization of the microbiome and examination of pediatric populations.In this review,we summarize studies that have investigated the microbiome in PSC and PSC-IBD as well as putative mechanisms,including the potential role of metabolites,such as BAs.We then briefly review the evidence for interventions with microbe-altering properties for treating PSC. | Rebecca Little Eytan Wine Binita M Kamath Anne M Griffiths Amanda Ricciuto | 2020 | World Journal of Gastroenterology2020，26，21： | 5 |
| 3 | Continuing episodes of pain in recurrent acute pancreatitis: Prospective follow up on a standardised protocol with drugs and pancreatic endotherapy显示文摘AIM To assess the outcomes of drug therapy(DT)followed by pancreatic endotherapy for continuing painful episodes in recurrent acute pancreatitis.METHODS DT comprised of pancreatic enzymes and antioxidants failing which,endotherapy(ET;pancreatic sphincterotomy and stent placement)was done.The frequency of pain,its visual analogue score(VAS),quality of life(Qo L),serum C peptide and faecal elastase were compared between baseline and after 1 year of follow up in all patients and in the two subgroups on DT and ET.Response was defined as at least 50%reduction in the severity of pain to below a score of 5.RESULTS Of the thirty nine patients analysed,21(53.9%)responded to DT and 18(46.1%)underwent ET.The VAS for pain(7.0±2.0 vs 1.3±2.5,P<0.001)and the number of days with pain per month decreased[1.0(1.0,2.0)vs 1.0(0.0,1.0),P<0.001],and the Qo L scores[55.0(44.0,66.0)vs 38.0(32.00,51.00),P<0.01]improved significantly during follow up.Similar significant improvements were seen in patients in the subgroups of DT and ET except for Qo L in ET.The serum C-peptide(P=0.001)and FE(P<0.001)levels improved significantly in the entire group and in the two subgroups of patients except for the C peptide levels in patients on DT.CONCLUSION A standardised protocol of DT,followed by ET decreased the intensity and frequency of pain in recurrent acute pancreatitis,enhanced Qo L and improved pancreatic function. | C Ganesh Pai M Ganesh Kamath Mamatha V Shetty Annamma Kurien | 2017 | World Journal of Gastroenterology2017，23，19： | 2 |
| 4 | The AO/ASIF proximal femoral nail antirotation (PFNA):a new design for the treatment of unstable proximal femoral fractures显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2009 | Injury2009，40，4： | 1 |
| 5 | Graphite particles reinforced ZA-27 alloy composite materials for journal bearing applications 显示文摘 | Sharma S C Girish B M Kamath R | 1998 | Wear1998，219，2： | 1 |
| 6 | The AO/ASIF proximai femoral nail antirotation(PFNA) :a new design for the treatment of unstable proximal femoral fractures 显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2009 | Injury2009，4，： | 1 |
| 7 | Idealized hysteresis modeling of electrorheological and magnetorheological dampers 显示文摘 | Wereley N M Pang L Kamath G M | 1998 | Journal of Intelligent Material Systems and Structures1998，9，8： | 1 |
| 8 | The AO/ASIF proxi-mal femoral nail antirotation(PFNA):a new design for the treatmentof unstable proximal femoral fractures显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2008 | Orthop Trauma2008，10，： | 1 |
| 9 | The AO/ASIF proximalfemoral nail antirotation(PFNA):a new design for the treatment of un-stable proximal femoral fractures显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2009 | Injury2009，40，4： | 1 |
| 10 | The AO/ASIF proximal femoral nail antirotation (PFNA): a new design for the treatment of unstable proximal femoral fractures显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2009 | Injury2009，40，4： | 1 |
| 11 | A model to predict sur-vival in patients with end-stage liver disease显示文摘 | Kamath PS Wiesner RH Malinchoc M | 2001 | Hepatology2001，33，2： | 1 |
| 12 | Electrical energy storage for the grid:a battery of choices显示文摘 | DUNN B KAMATH H ARASCON J M | 2011 | Science2011，334，6058： | 1 |
| 13 | A model to predict survival in patients with end-stage liver disease显示文摘 | Kamath PS Wiesner RH Malinchoc M | 2001 | Hepatology2001，33，2： | 1 |
| 14 | Mesenteric venous thrombosis 显示文摘 | Kumar S Sarr M G Kamath P S | 2001 | N Eng[J Med2001，345，9： | 1 |
| 15 | The AO/ ASIF proximal nail antirotation (PFNA) : a new design for the treatment of unstable proximal femoral fractures 显示文摘 | Mereddy P Kamath S Ramakrishnan M | 2009 | In- jury2009，40，4： | 1 |
| 16 | The impact of stop- ping inhibitors of the renin-angiotensin system in patients with ad- vanced chronic kidney disease 显示文摘 | Ahmed AK Kamath NS EI Kossi M | 2010 | Nephrol Dial Transplant2010，25，12： | 1 |
| 17 | A model to predict survival in patients with end-stage liver disease显示文摘 | Kamath PS Wiesner RH Malinchoc M | | Hepatology0，33，： | 1 |
| 18 | The AO/ASIF proximal femoral nail antirotation (PFNA); a new de- sign for the treatment of unstable proximal femoral fractures显示文摘 | MEREDDY P KAMATH S RAMAKRISHNAN M | 2009 | Injury2009，40，4： | 1 |
| 19 | Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis显示文摘 | Kamath A T Feng C G Macdonld M | 1999 | Infect Immun1999，67，： | 1 |
| 20 | Effect of SiC particle reinforcement on the unlubricated sliding wear behaviour of ZA-27 alloy composites 显示文摘 | Sharma S C Girish B M Kamath R | 1997 | Wear1997，213，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员